Inventor · disambiguated record
John Emerson Bisi
Also filed as: BISI JOHN E · BISI JOHN EMERSON
23 granted patents·21 pending applications·251 citations·filing 2009–2024
97Inventor score
Files withG1 THERAPEUTICS INC40DIROCCO DEREK P1INCYCLIX BIO LLC1SHARPLESS NORMAN E1UNIV NORTH CAROLINA1
Top patents by PatentIndex Score
44 records- 0198US11040042B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·5 cites·2 claims
- 0298US10085992B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Oct 2, 2018·16 cites·9 claims
- 0398US10076523B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2016·Granted Sep 18, 2018·15 cites·15 claims
- 0498US9931345B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·14 cites·20 claims
- 0598US9527857B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2014·Granted Dec 27, 2016·31 cites·74 claims
- 0698US9487530B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Nov 8, 2016·36 cites·50 claims
- 0798US9464092B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Oct 11, 2016·29 cites·54 claims
- 0897US11717523B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 0997US11654148B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2021·Granted May 23, 2023·4 cites·16 claims
- 1097US10434104B2HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·7 cites·10 claims
- 1196US10925878B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·5 cites·85 claims
- 1296US10709711B2Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·6 cites·8 claims
- 1396US10660896B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·5 cites·21 claims
- 1496US9717735B2Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2015·Granted Aug 1, 2017·16 cites·60 claims
- 1595US11090306B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2019·Granted Aug 17, 2021·9 cites·6 claims
- 1695US10966984B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·5 cites·30 claims
- 1795US10413547B2Treatment of Rb-negative tumors using topoisomerase with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Sep 17, 2019·11 cites·3 claims
- 1894US12285431B2Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitorsG1 THERAPEUTICS INC·Filed 2021·Granted Apr 29, 2025·2 cites·9 claims
- 1993US11395821B2Treatment of EGFR-driven cancer with fewer side effectsG1 THERAPEUTICS INC·Filed 2019·Granted Jul 26, 2022·9 cites·7 claims
- 2092US10376519B2Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2017·Granted Aug 13, 2019·5 cites·10 claims
- 2192US10231969B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumorsG1 THERAPEUTICS INC·Filed 2017·Granted Mar 19, 2019·12 cites·13 claims
- 2291US11446295B2Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumorsG1 THERAPEUTICS INC·Filed 2019·Granted Sep 20, 2022·4 cites·6 claims
- 2389US2023381189A1Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2488US2023364098A1Hspc-sparing treatments for rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2582US2023248733A1Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2674US2019167691A1Transient protection of hematopoietic stem and progenitor cells against ionizing radiationG1 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2774US2021077498A1Transient protection of hematopoietic stem and progenitor cells against ionizing radiationG1 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2873US2023241059A1Anti-neoplastic combinations and dosing regimens using cdk4/6 inhibitor compounds to treat rb-positive tumorsG1 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2972US2020345743A1Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3071US2014274896A1Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing RadiationG1 THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3170US2018303838A1Transient protection of hematopoietic stem and progenitor cells against ionizing radiationG1 THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3270US2025199015A1Cyclin-dependent kinase 2 inhibitors for medical treatmentINCYCLIX BIO LLC·Filed 2024·Application pending·0 cites
- 3368US2017119774A1Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing RadiationG1 THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3465US2011224227A1Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitorsSHARPLESS NORMAN E·Filed 2009·Application pending·0 cites
- 3565US2016045509A1Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing RadiationG1 THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3664US2017246171A1Treatment Of RB-Negative Tumors Using Topoisomerase Inhibitors In Combination With Cyclin Dependent Kinase 4/6 InhibitorsG1 THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3763US2014271460A1Highly Active Anti-Neoplastic and Anti-Proliferative AgentsG1 THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3863US2015111896A1Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitorsUNIV NORTH CAROLINA·Filed 2014·Application pending·0 cites
- 3963US2018015096A1Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4062US9808461B2Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6DIROCCO DEREK P·Filed 2011·Granted Nov 7, 2017·2 cites·21 claims
- 4160US2016310499A1Highly Active Anti-Neoplastic and Anti-Proliferative AgentsG1 THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4259US2023146638A1Treatment of EGFR-Driven Cancer with Fewer Side EffectsG1 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4352US2021030758A1Treatment of cancers having driving oncogenic mutationsG1 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4442US2016220569A1CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During ChemotherapyG1 THERAPEUTICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when John Emerson Bisi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →